骨髄移植(Bone Marrow Transplantation)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Bone Marrow Transplantation Overview 8
Therapeutics Development 9
Pipeline Products for Bone Marrow Transplantation – Overview 9
Pipeline Products for Bone Marrow Transplantation – Comparative Analysis 10
Bone Marrow Transplantation – Therapeutics under Development by Companies 11
Bone Marrow Transplantation – Therapeutics under Investigation by Universities/Institutes 12
Bone Marrow Transplantation – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Bone Marrow Transplantation – Products under Development by Companies 16
Bone Marrow Transplantation – Products under Investigation by Universities/Institutes 17
Bone Marrow Transplantation – Companies Involved in Therapeutics Development 18
Anchor Therapeutics, Inc. 18
Boryung Pharmaceutical Co., Ltd. 19
Cantex Pharmaceuticals, Inc. 20
Cellerant Therapeutics, Inc. 21
Cleveland BioLabs, Inc. 22
Compugen Ltd. 23
Mesoblast Limited 24
Pluristem Therapeutics Inc. 25
Proteonomix, Inc. 26
Spectrum Pharmaceuticals, Inc. 27
Taiga Biotechnologies, Inc. 28
Wellstat Therapeutics Corporation 29
Bone Marrow Transplantation – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
(filgrastim + plerixafor) – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ATI-2341 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BR-05001 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
CBLB-612 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Cell Therapy for Bone Marrow Transplantation – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CGEN-15001 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
melphalan – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MPC-CBE – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
PGX-100 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PLX-RAD – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
PN-951 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Protein for Bone Marrow Transplantation – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
romyelocel-L – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Small Molecules to Inhibit Perforin for Bone Marrow Transplantation – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Bone Marrow Transplantation – Recent Pipeline Updates 60
Bone Marrow Transplantation – Dormant Projects 70
Bone Marrow Transplantation – Discontinued Products 71
Bone Marrow Transplantation – Product Development Milestones 72
Featured News & Press Releases 72
Mar 03, 2015: Pluristem and Hadassah Medical Center Announce Significant Data Showing PLX-R18 Cells Improve Bone Marrow Transplantation 72
Dec 04, 2014: Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes 73
Nov 13, 2014: Cell Source’s Megadose Drug Combination Receives Regulatory Approval in Italy to Commence Human Clinical Trials 74
Oct 27, 2014: Case Western Reserve University to Study Pluristem’s PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases 74
Apr 23, 2014: Spectrum Pharmaceuticals’ Pivotal Trial of Captisol-Enabled Melphalan Meets Primary Endpoint 75
May 07, 2013: Pluristem Develops PLX-RAD Cells For Use In Hematology 76
Sep 05, 2012: Pluristem Therapeutics Announces Successfully Treatment Of Third Critically Ill Patient With PLX Cells Under Compassionate Use 77
May 09, 2012: Pluristem’s PLX Cells Saves Life Of Child After Bone Marrow Transplantation Failure 78
Feb 01, 2012: Ligand Presents Successful Phase II Results For Captisol-Enabled, Propylene Glycol-Free Melphalan At BMT Tandem Meetings 79
Jul 07, 2011: Mesoblast Receives FDA Clearance For Phase III Bone Marrow Transplant Trial 80
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83